Literature DB >> 11388438

Rolipram reduces excitotoxic neuronal damage.

F Block1, W Schmidt, M Nolden-Koch, M Schwarz.   

Abstract

Proinflammatory cytokines are supposed to be involved in the pathophysiology of neuronal damage following excitotoxic lesions. We examined the effect of rolipram, a TNF-alpha-inhibitor, on excitotoxic neuronal damage. Quinolinic acid (240 nmol in 1 microl) was injected stereotactically into the striatum of male Wistar rats. Four groups of QA rats were treated i.p. with solvent, MK-801 (4 mg/kg) or rolipram (0.3 mg/kg) which was started either 6 or 24 h after QA injection and continued with daily applications for 14 days. QA injection induced neuronal damage which affected 93% of the striatal area. MK-801 reduced this damage to 12% of the striatal area. Treatment with rolipram when started at 6 h after QA injection resulted in neuronal damage amounting to 60%; the result after starting at 24 h was not different from solvent (91%). The present results demonstrate that rolipram reduces neuronal damage induced by intrastriatal QA application.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11388438     DOI: 10.1097/00001756-200105250-00041

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  10 in total

Review 1.  Phosphodiesterase inhibitors as therapeutics for traumatic brain injury.

Authors:  David J Titus; Anthony A Oliva; Nicole M Wilson; Coleen M Atkins
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

2.  Postinjury treatment with rolipram increases hemorrhage after traumatic brain injury.

Authors:  C M Atkins; Y Kang; C Furones; J S Truettner; O F Alonso; W D Dietrich
Journal:  J Neurosci Res       Date:  2012-04-26       Impact factor: 4.164

3.  Systemic administration of rolipram increases medullary and spinal cAMP and activates a latent respiratory motor pathway after high cervical spinal cord injury.

Authors:  Satkunendrarajah Kajana; Harry G Goshgarian
Journal:  J Spinal Cord Med       Date:  2009       Impact factor: 1.985

4.  Phosphodiesterase isoform-specific expression induced by traumatic brain injury.

Authors:  Anthony A Oliva; Yuan Kang; Concepcion Furones; Ofelia F Alonso; Olga Bruno; W Dalton Dietrich; Coleen M Atkins
Journal:  J Neurochem       Date:  2012-11-01       Impact factor: 5.372

5.  Treatment with the phosphodiesterase type-4 inhibitor rolipram fails to inhibit blood--brain barrier disruption in multiple sclerosis.

Authors:  Bibiana Bielekova; Nancy Richert; Thomas Howard; Amy N Packer; Gregg Blevins; Joan Ohayon; Henry F McFarland; Claus-Steffen Stürzebecher; Roland Martin
Journal:  Mult Scler       Date:  2009-09-23       Impact factor: 6.312

6.  Protective Effects of Forskolin on Behavioral Deficits and Neuropathological Changes in a Mouse Model of Cerebral Amyloidosis.

Authors:  Brice Ayissi Owona; Caroline Zug; Hermann J Schluesener; Zhi-Yuan Zhang
Journal:  J Neuropathol Exp Neurol       Date:  2016-05-31       Impact factor: 3.685

7.  Phosphodiesterase 4 and 7 inhibitors produce protective effects against high glucose-induced neurotoxicity in PC12 cells via modulation of the oxidative stress, apoptosis and inflammation pathways.

Authors:  Nazanin Namazi Sarvestani; Saeedeh Saberi Firouzi; Reza Falak; Mohammad Yahya Karimi; Mohammad Davoodzadeh Gholami; Akram Rangbar; Asieh Hosseini
Journal:  Metab Brain Dis       Date:  2018-04-30       Impact factor: 3.584

8.  The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injury.

Authors:  Sandra Marie Schaal; Maneesh Sen Garg; Mousumi Ghosh; Lilie Lovera; Michael Lopez; Monal Patel; Jack Louro; Samik Patel; Luis Tuesta; Wai-Man Chan; Damien Daniel Pearse
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

Review 9.  Pharmacological Modulation of Functional Phenotypes of Microglia in Neurodegenerative Diseases.

Authors:  Gyun Jee Song; Kyoungho Suk
Journal:  Front Aging Neurosci       Date:  2017-05-15       Impact factor: 5.750

Review 10.  Divergent roles for tumor necrosis factor-alpha in the brain.

Authors:  Krishnan Sriram; James P O'Callaghan
Journal:  J Neuroimmune Pharmacol       Date:  2007-03-31       Impact factor: 7.285

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.